Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Non-Current Liabilities (2016 - 2020)

Niagen Bioscience (NAGE) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $20.2 million as the latest value for Q2 2020.

  • Quarterly Total Non-Current Liabilities fell 30.73% to $20.2 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $20.2 million through Jun 2020, down 30.73% year-over-year, with the annual reading at $19.6 million for FY2019, 32.84% up from the prior year.
  • Total Non-Current Liabilities for Q2 2020 was $20.2 million at Niagen Bioscience, up from $18.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $29.1 million in Q2 2019, with the low at $6.6 million in Q4 2016.
  • Average Total Non-Current Liabilities over 5 years is $14.0 million, with a median of $13.2 million recorded in 2016.
  • The sharpest move saw Total Non-Current Liabilities soared 153.45% in 2019, then plummeted 30.73% in 2020.
  • Over 5 years, Total Non-Current Liabilities stood at $9.4 million in 2016, then fell by 8.66% to $8.6 million in 2017, then skyrocketed by 72.33% to $14.8 million in 2018, then soared by 32.84% to $19.6 million in 2019, then rose by 2.69% to $20.2 million in 2020.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $20.2 million, $18.8 million, and $19.6 million for Q2 2020, Q1 2020, and Q4 2019 respectively.